Zilebesiran

iStock, Jackie Niam While Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s commercial prospects. Alnylam was flying high one year ago. The RNAi pioneer’s share price was rising ever closer to $500 apiece amid the rapid growth of its transthyretin-mediated amyloidosis (ATTR) franchise thanks to a March 2025 FDA nod and the progress of late-phase programs. Today, the stock has fallen to around $250. The company’s share price collapsed when management lowered full-year guidance in July. Sales of TTR silencer Amvuttra for the second quarter fell short of analyst expectations and Alnylam reduced its full-year guidance by about $200 million. The news raised doubts about the RNAi product’s prospects in a market served by small-molecule TTR stabilizers from BridgeBio Pharma and Pfizer. Earnings Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise Alnylam’s revenue cut “may create a near term credibility overhang and could “raise questions on peak sales potential, even if there’s tailwinds in the competitive landscape,” according to Stifel. July 31, 2026 · 2 min read · Tristan Manalac Read more Guggenheim Securities analysts set out the concerns raised by the revised guidance in a July 31 note to investors. The cut, which happened despite Amvuttra being the “sole, differentiated modality” in ATTR cardiomyopathy (ATTR-CM), suggested that the commercial opportunity is smaller than expected, the drug is mispriced or TTR stabilizers are becoming the preferred modality, the analysts said. Alnylam’s stock has yet to recover. However, while the Guggenheim team was “on the sidelines on the stock” even before the guidance cut, other analysts have retained faith in a comeback. TD Cowen assigned a $482 price target to Alnylam back in November 2025, when the stock traded above $430. The analysts reiterated the target last month, even as Alnylam traded below $250. The debates driving Alnylam’s stock BMO Capital Markets analysts, who began covering Alnylam in August with a $318 price target, set out three key debates about the biotech’s prospects in an Aug. 18 note to investors. Alnylam bulls and bears are split on multiple questions, the analysts said—about the size of the ATTR market, whether the company’s next-generation RNAi candidate nucresiran creates value and the likelihood of gene silencing becoming a major drug modality. The BMO team sided with the bulls on each point, arguing that Alnylam cut its guidance because the population of patients that Amvuttra served most urgently—those for whom stabilizers hadn’t worked—"exhausted sooner than expected.” Through that perspective, the guidance cut changed the shape of the sales ramp, not the size of the opportunity. “The path to $10 billion+ in franchise sales was never through the second-line,” the analysts wrote, “it always ran through front-line starts and expansion of the diagnosed population.” cardiovascular disease ‘Worse than expected’ Wainua data muddies water for TTR silencers AstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin silencer trial “further confuses the picture” for Wainua when combined with the standard of care for ATTR-CM, analysts say. August 28, 2026 · 2 min read · Gabrielle Masson Read more As the analysts acknowledge, there is another way to view the guidance cut. An Alnylam bear may argue that cutting sales guidance two quarters into the ATTR-CM launch says something about the size of the pool. Another skeptical reading is that, having burned through the second-line market, Alnylam faces the harder challenge of competing with Pfizer’s Vyndamax and BridgeBio’s Attruby for first-line patients. Alnylam is running Phase 3 trials of nucresiran in ATTR-CM and ATTR with polyneuropathy (ATTR-PN)—the indication for which Amvuttra was first approved, back in 2022. The late-stage failure of AstraZeneca and Ionis’ Wainua in ATTR-CM in July raised questions about nucresiran, but after the dust settled, analysts became more comfortable with Alnylam’s prospects. In a Sept. 3 note, Stifel analysts said endpoint selection and patient enrollment drove Wainua’s failure. That view, which was echoed by BMO analysts, suggests Alnylam “is positioned for success with their event-driven study that is enriched for earlier-stage patients,” the Stifel team said. The broadening RNAi pipeline Beyond ATTR, Alnylam is applying its technology to big markets including hypertension and Alzheimer’s disease. BMO analysts compared gene silencing today to where monoclonal antibodies were in the late 1990s. Antibody developers ignored doubters and established a new, major modality. If gene silencing biotechs do the same, “Alnylam will own the success” more than any other company, BMO analysts said. A Phase 3 cardiovascular outcomes trial of blood pressure prospect zilebesiran “tests whether RNAi can be delivered to a population-scale chronic indication,” BMO analysts said. A successful readout “could unlock a significant commercial opportunity and highlight the value of Alnylam’s ex-ATTR franchise,” the analysts added in a Sept. 17 note. Still, skepticism abounds. Stifel analysts, also writing on Sept. 17, said they “remain cautious on the safety pro continue to question whether the modest [blood pressure] reductions observed in [Phase 2] are sufficient to drive a clinically meaningful [cardiovascular outcomes trial] benefit.” Alnylam is betting that consistent, modest blood pressure reductions can cut the risk of cardiovascular events. Earnings BridgeBio continues ATTR ascent as Alnylam’s Amvuttra falls short of expectations BridgeBio Pharma’s transthyretin amyloidosis medicine Attruby is off to a strong launch, while Alnylam lowered full-year sales guidance for competitor Amvuttra. August 12, 2026 · 2 min read · Tristan Manalac Read more If that bet pays off, Alnylam could cement its position at the forefront of RNAi therapeutics. ADARx Pharmaceuticals’ $446.3 million IPO in September and the 2025 deal between Novartis and China’s Argo Biopharmaceutical illustrate the growing and increasingly global nature of the sector. But Alnylam was the pioneer, and its market cap is several-fold larger than its closest biotech rivals. Having turned its first-mover advantage into a $3.3 billion cash cushion, Alnylam is considering striking deals for drug candidates and technologies for delivering therapies to new tissues, Stifel analysts said. Alnylam is looking at areas that are complementary to what it is already working on from a commercial and R&D perspective, the analysts added. Alnylam also has opportunities to reignite enthusiasm for its internal pipeline. This year, the biotech is set to publish Phase 2 data on a bleeding disorder drug candidate, as well as Phase 1 results on Huntington’s disease and obesity programs. Alnylam is aiming to report five or more key readouts in 2027 and in 2028. .responsive-container { display: flex; flex-wrap: wrap; border: 1px solid #ededed; font-family: Helvetica, Arial, Sans-Serif; padding: 20px 20px 10px 20px; } .column-left { flex: 1; max-width: 45%; padding: 20px 20px 10px 20px; } .column-right { flex: 2; padding: 20px 20px 10px 20px; } @media (max-width: 768px) { .column-left, .column-right { max-width: 100%; flex: 100%; padding: 10px 0; } } Subscribe to BioPharm Executive! Market insights, trending business and policy stories for biopharma leaders hbspt.forms.create({ region: "na1", portalId: "4413123", formId: "7c139b3c-ff0b-44e0-bffe-f449801dca59", onFormSubmitted: function($form, data) { window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'GTMevent', 'event_name': 'newsletter_sign_up' }); } });

一段流传千年的医案 东汉末年，神医华佗路经市集。三个壮汉正围桌饮酒，其中一人面色绯红、神采飞扬，引得旁人啧啧称赞。 众人羡慕他气色红润，大汉也颇为得意。 华佗却驻足摇头："此人面红如枣，乃阳亢之象，命不久矣。" 果不其然，数日之后，那大汉暴毙而亡。 这，或许是人类历史上关于高血压最早的记载。 千年前，华佗只能"望闻问切"；千年后，血压计早已走进千家万户。可令人遗憾的是——高血压带来的威胁，从未远去，反而愈演愈烈。什么是高血压？它为何被称为"沉默杀手"？ 高血压，是指体循环动脉血压持续升高为主要特征的临床综合征——收缩压≥140mmHg，舒张压≥90mmHg，即可诊断。 它之所以"沉默"，是因为多数患者在早期几乎没有任何明显症状，却在悄无声息中损害着心、脑、肾等重要器官。 数据令人心惊： 全球高血压患者已突破12.8亿 高血压是中风的首要危险因素，约70%的脑卒中死亡与之相关 是50%心肌梗死、心力衰竭、主动脉瘤等重症的关键推手 也是慢性肾病的重要起因 即使是轻度血压升高，也会缩短预期寿命 专家直言：高血压是诱发冠心病的独立危险因子，更是预防猝死最有力的检测指标。 它从不声张，却可能在某一天，毫无征兆地夺走生命。高血压大爆发：每3个成年人就有1个中招 1958年，中国成人高血压患病率仅5%。 半个多世纪过去，情况发生了翻天覆地的变化： 2021—2022年全国调查显示，中国成人高血压患病率已达31.6% 每3名成年人中就有1名高血压患者 患者总人数高达3.3亿——比整个美国的人口还要多 更令人担忧的是，患病呈现明显年轻化趋势：20~39岁青年高血压患病率从1991年的4.5%飙升至近年13.4% 农村地区患病率已反超城市，与城镇化进程中的饮食结构改变密切相关 高血压不再是"老年病"，它正在向每一位年轻人步步逼近。 传统治疗的两难困境 面对高血压，传统治疗有两大路径，但都面临各自的困境： 一般治疗——生活方式的"自我救赎" 控制体重、减少钠盐、补充钙钾、坚持运动、戒烟限酒、舒缓压力……这些方法有效，但考验的是日复一日的自律。 药物治疗——无奈的"试错循环" 利尿药、钙通道阻滞剂、血管紧张素转换酶抑制剂……药物种类繁多，但不同机体对不同药物的适应性差异较大。 很多患者陷入"尝试新药→效果不佳→再换新药"的恶性循环： 耽误宝贵治疗时间 加重药物对肝肾功能的损伤 长期使用产生耐药性，疗效下降 而一个更残酷的现实是——中国近3亿高血压患者，血压控制达标率不足20%。服药依从性差，是血压失控的最大元凶。 难道，高血压真的只能"带着过一辈子"吗？ 未必。医学新曙光一：干细胞疗法，从"治标"走向"治本" 近年来，随着再生医学的飞速发展，一种全新的思路正在改变高血压的治疗格局——干细胞疗法。 干细胞为什么能治高血压？ 干细胞具有多向分化潜能，在一定条件下可以： 分化为血管内皮细胞 ，修复受损血管 分化为心肌细胞 ，修复心脏功能 软化血管、增加弹性 ，从根源上改善血压状况 更关键的是，它还能分化为肝脏、肾脏等功能细胞，全面修复高血压患者受损的身体，减轻并发症。 一个形象的比喻 人体的血管，由血管内皮细胞和血管平滑肌细胞构成。 你可以把它们想象成血管的"内衬"和"骨架"—— 内皮细胞为血液流动提供光滑的"跑道"，并分泌一氧化氮等"保护因子"，抵御动脉粥样硬化和血栓 一旦内皮细胞受损脱落，血小板就会堆积，血栓与高血压随之而来 而干细胞，就是那位"万能修理工"： 它生成新的血管内皮细胞，重建"光滑跑道" 它新生血管平滑肌细胞，预防和治疗动脉硬化，恢复血管顺应性 从"治标"到"治本"，这或许是高血压治疗理念的一次革命。 最新科研突破：2025年多项权威印证 2025年，多个权威期刊的研究进一步验证了干细胞的降压价值： **《Stem Cells and Development》**系统综述明确：间充质干细胞（MSCs）可通过调节肠道菌群、消除慢性炎症、修复血管结构实现血压调控 **《Cells》**动物实验证实：MSCs能改善代谢性炎症、减少组织纤维化，间接稳定血压 临床前数据显示：MSCs输注可使高血压大鼠收缩压下降约20%，肾纤维化程度减少50% 更令人振奋的是，2025年《Science China Life Sciences》发表突破性研究，首次解锁了干细胞的全新降压机制——干细胞优先归巢至脾脏，通过激活交感神经、调控神经递质这一"神经免疫联动"通路扩张血管、降低血压，为顽固性高血压提供了全新研究方向。 医学新曙光二：新药"井喷"，打破十余年沉寂 如果说干细胞代表了"修复式"的未来，那么近年来的新药研发，则正在改变"服药"的传统认知。 半年一针的siRNA降压药 2026年6月，国家药监局拟将全球首款小干扰RNA（siRNA）降压药Zilebesiran纳入突破性治疗品种。这款药物： 每半年皮下注射一次 即可平稳降压 临床研究显示，单次注射300mg后，3个月收缩压较安慰剂组平均下降16.7mmHg，疗效可持续6个月 通过精准靶向降解肝脏中的血管紧张素原，从源头抑制升压信号 一句话：从"天天吃药"到"半年一针"，服药体验正在被彻底颠覆。 全球首款每周一次的口服降压药 2026年9月，国家药监局批准全球首款每周只需服用一次的长效降压药上市。 降压效果与每日服药方案相当，血压波动更小 服药依从性从传统方案的约65%提升至95%以上 定价每月180元，已进入医保报销目录 对老年患者和农村地区患者而言，这无疑是巨大福音。 全球首个醛固酮合成酶抑制剂获批 2026年5月，阿斯利康的Baxdrostat在美国获批上市，这是全球首个高选择性醛固酮合成酶抑制剂。 针对传统药物难以控制的"未控制/难治性高血压" III期临床试验显示：52周时收缩压较基线平均下降12.6mmHg，超过52%的患者血压达标 开创了靶向醛固酮失调的全新降压途径医学新曙光三：真实案例，干细胞如何在临床上"发力" 理论再好，不如数据说话。近年来，多项临床研究给出了令人振奋的答案。 案例一：脑卒中（中风） 2014年 · 江西 江西省人民医院针对49例急性脑卒中患者，采用鞘内注射自体间充质干细胞。结果显示：移植后1、6、12个月，患者神经功能评分显著改善，运动功能与生活能力明显提升；12个月后复查，均未见异常。 2017年 · 香港 香港中文大学发布自体间充质干细胞静脉移植治疗慢性脑卒中的研究，随访一年证实：干细胞移植安全，并能有效改善慢性脑卒中患者的神经功能恢复。 2020年 · 国家层面 一款针对缺血性脑卒中的干细胞新药（"缺血耐受人同种异体骨髓间充质干细胞"）已获国家药监局临床试验默示许可。 2025年 · 国内临床 中国人民解放军第303医院（合作医院）针对高血压脑出血患者的研究显示，干细胞治疗组总有效率达95%，显著高于对照组的75%；患者的语言、肌张力、肌力恢复情况明显优于常规治疗。 案例二：心力衰竭（心衰） 2018年8月，《循环研究》杂志公布干细胞疗法治疗心衰的III期临床试验结果： 治疗组六分钟步行距离相对改善20.5% 40% 的患者心功能分级改善1个级别 六个月时生活质量评分相对改善31% 2026年8月 · 《自然·医学》重磅突破 南京艾尔普与南京大学附属鼓楼医院团队完成全球首个iPSC（诱导多能干细胞）随机对照临床研究： 90%重症心衰患者心功能显著恢复 无肿瘤、恶性、心律紊乱等严重副作用 标志着心衰治疗从"延缓衰竭"正式迈入"主动修复"新时代 案例三：肾功能损伤 日本湘南镰仓综合医院采用自体CD34+干细胞治疗顽固性高血压合并肾损伤患者： 治疗后血肌酐水平显著下降 原本依赖多种药物的降压方案简化为单一用药 修复受损肾小管，改善肾脏缺血状态 政策东风：中国干细胞治疗进入"元年" 2025年被业界公认为"中国干细胞治疗产业化元年"，一系列里程碑事件接连落地： 2025年1月 ：国家药监局批准首款国产干细胞药物"艾米迈托赛注射液"上市 2025年6月 ：北京大学人民医院开出首张处方，正式开启商业化应用 2025年10月 ：国务院公布《生物医学新技术临床研究和临床转化应用管理条例》，为干细胞转化应用构建了清晰合法的路径 2026年5月 ：条例正式实施，干细胞治疗从"临床研究"迈向"临床应用"有法可依 目前国内已有120多款干细胞药物进入临床试验，覆盖心血管、肾脏、呼吸等众多领域 更值得期待的是成本的大幅下降：国产首款干细胞药定价仅1.98万元，而同款美国药物单次治疗费用高达约137万元——这意味着，前沿治疗正在从"天价"走向"亲民"。结语：高血压，终将"无所遁形" 现代医学已经证明： 干细胞疗法 可以修复受损血管、重建心脏功能、逆转器官损伤 新一代靶向药物 让"天天吃药"成为历史，"半年一针"成为现实 AI与可穿戴设备 让血压监测进入"全天候"时代 当然，我们必须清醒地认识到——无论是干细胞疗法还是新药研发，目前仍处于临床探索与逐步成熟的阶段，患者应在专业医生指导下科学选择治疗方案，切勿盲目追求"神奇疗法"。 但我们也坚信： 从华佗的"望闻问切"，到今天的细胞疗法； 从"终身服药"的无奈，到"半年一针"的从容—— 医学的每一次进步，都在把那个"沉默的杀手"一点点逼向绝路。 终有一天，高血压将无所遁形。 在那一天到来之前—— 请管住嘴、迈开腿、常测压、遵医嘱。 爱护自己，就是保护家人。